رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06768827 (NMoO) لـ Obesity and Overweight، مقاومة الأنسولين، Obesity and Obesity-related Medical Conditions هي لم يبدأ التجنيد بعد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
New Mechanisms of Obesity (NMoO)
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ 'رادار التجارب AI' أن يساعدك؛ ما عليك سوى النقر على 'وصف الدراسة' لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06768827 (NMoO) هي دراسة تدخُّلية لـObesity and Overweight، مقاومة الأنسولين، Obesity and Obesity-related Medical Conditions وهي لم يبدأ التجنيد بعد. من المقرر أن يبدأ التسجيل في ١٠ جمادى الأولى ١٤٤٧ هـ لتجنيد ٥٥ مشاركًا. يقودها جامعة ييل، ومن المتوقع اكتمالها بحلول ٢٦ ذو القعدة ١٤٥١ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٤ ربيع الآخر ١٤٤٧ هـ.
الملخص
Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.
وصف مفصل
Pediatric obesity is a major health burden affecting millions of children and adolescents as it predisposes to the development of cardio-metabolic diseases early in life, such as insulin resistance, fatty liver disease and type 2 diabetes. Investigators have recently completed a series of studies to understand the relationship between the intestinal microbial activity and human metabolism in youth. It was observed that intestinal fermentation, a process through which fermentable carbohydrates are processed by intestinal bacteria, results in a variety of biological responses aimed at protecting the human body from developing obesity and some of its metabolic complications, such as insulin resistance and ectopic fat accumulation. In particular, investigators observed that intestinal fermentation causes 1- a reduction of plasma free fatty acids (FFA), due to the inhibition of adipose tissue lipolysis (ATL); 2- a marked entero-endocrine response to reduce appetite, characterized by an increase in the production of peptide YY (PYY) and glucagon-like peptide1 (GLP-1) and a reduced production of ghrelin. In addition, investigators observed that some intestinal fermentation responses are impaired in youth with obesity and insulin resistance (OIR). In light of this evidence, the current proposal will address: 1- how adipose tissue lipolysis response to intestinal fermentation is affected by insulin resistance; 2- whether changes in ATL, observed when fermentation occurs, are also associated with a reduction of glycerol derived neo-gluconeogenesis; 3- if physical activity may restore the entero-endocrine and adipose tissue response to intestinal fermentation in youth with insulin resistance. This is the first study to test the effect of insulin resistance on the relationship between intestinal microbial metabolic activity and human metabolism (namely adipose tissue lipolysis, gluconeogenesis and entero-endocrine response). The results obtained will provide fundamental insight into how insulin resistance occurring in youth with obesity affects the metabolic response to fermentable carbohydrates. In fact, despite the large body of literature showing an association between intestinal microbial fermentation and human metabolism, how and whether insulin resistance may modulate this association remains unknown.
العنوان الرسمي
Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications
الحالات الطبية
Obesity and Overweightمقاومة الأنسولينObesity and Obesity-related Medical Conditionsمعرّفات دراسة أخرى
- NMoO
- 2000038988
- 1R01DK140672-01A1 (منحة/عقد NIH الأمريكي)
NCT معرّف
تاريخ البدء (فعلي)
2025-11
آخر تحديث مُنشور
2025-09-26
تاريخ الاكتمال (المقدر)
2030-03-31
عدد المشاركين المخطط لهم
٥٥
نوع الدراسة
تدخُّلية
المرحلة
غ/م
الحالة
لم يبدأ التجنيد بعد
الكلمات الرئيسية
Obesity
Youth
Insulin Resistance
Intestinal Fermentation
Youth
Insulin Resistance
Intestinal Fermentation
الغرض الأساسي
علوم أساسية
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
لا شيء (مفتوحة)
مجموعات/التدخلات
| مجموعة المشاركين/مجموعة | تَدَخُّل/علاج |
|---|---|
تجريبيةRemote physical exercise | Lactulose Oral Product Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks. |
مقارن نشطControl physical excercise | Lactulose Oral Product Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks. |
النتيجة الرئيسية
النتيجة الثانوية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL) | Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration. | 6 hours |
CHANGES IN GLUCONEOGENESIS | Gluconeogenesis (GLC) will be measured using change in deuterium oxide concentration after colonic fermentation due to lactulose ingestion and compared between OIS and OIR. | 6 hours |
CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL) | Changes in ATL due to colonic fermentation will be measured in two groups of OIR youth. One group will undergo physical activity for 12 weeks and another group will undergo a control intervention. Lipolysis will be measured by using change in D5-glycerol concentration. | Baseline and 12 weeks |
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
CHANGES IN PEPTIDE YY (PYY) concentration | Changes in PYY concentration after lactulose intervention will be compared between OIS and OIR. | Baseline and 12 weeks |
CHANGES IN GHRELIN concentration | Changes in GHRELIN concentration after lactulose intervention will be compared between OIS and OIR. | Baseline and 12 weeks |
معايير الأهلية
الأعمار المؤهلة للدراسة
طفل, بالغ
العمر الأدنى للدراسة
15 Years
الجنس المؤهل
الكل
- Age 15 to 22 years
- In puberty (girls and boys: Tanner stage III-V);
- BMI >85th
- Pregnancy;
- endocrinopathies (e.g., Cushing syndrome);
- substance abuse;
- medications affecting insulin resistance such as metformin, GLP-1 analogues; -
- high fibers intake (> 30g/day) as assessed by a 3-day food record.
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
جهة اتصال مركزية للدراسة
جهة اتصال: NICOLA SANTORO, MD, PhD, 2037852819, [email protected]
1 مواقع الدراسة في 1 بلدان
Connecticut
Yale University, New Haven, Connecticut, 06520, United States